Do you have the same question? Follow this Question
Oct 24, 2024 - 01:53 PM
We’ve provided several answers to questions related to Steglatro (Ertugliflozin) , see some other helpful Q&A related to this product.
Question: Who should not use Steglatro?
Answer: Do not use Steglatro if you have severe kidney disease, are on dialysis, or are allergic to ertugliflozin. Avoiding these conditions ensures that the medication is safe and effective for the user.
Question: What special precautions should be taken when using Steglatro?
Answer: Before starting Steglatro, evaluate kidney function and correct volume status. Monitor for symptoms of ketoacidosis, dehydration, and low blood sugar. These precautions help in preventing serious adverse effects and ensuring the safe use of Steglatro.
Question: What is the active ingredient in Steglatro?
Answer: The active ingredient in Steglatro is Ertugliflozin. Knowing the active ingredient helps in understanding how the medication works to control blood sugar levels.
Question: What is the DrugBank identifier for Steglatro?
Answer: The DrugBank identifier for Steglatro is DB11827. This identifier allows access to comprehensive drug data, including mechanisms, interactions, and more.
Question: What is the protein binding percentage of Steglatro?
Answer: Steglatro has a protein binding percentage of 93.6%. High protein binding can affect the drug's distribution and interaction with other medications.
Question: What is the chemical name of Steglatro?
Answer: The chemical name of Steglatro is Ertugliflozin. Knowing the chemical name can help in understanding its active ingredient and potential interactions with other medications.
Question: What is the formula of Steglatro?
Answer: The formula of Steglatro is C22H25ClO7. The chemical formula represents the specific arrangement of atoms in the molecule, crucial for understanding its pharmacological properties.
